Omalizumab for the treatment of chronic spontaneous urticaria: association between body mass index and outcome
Introduction: Omalizumab has been recently registered as a third-line therapy for chronic spontaneous urticaria. Objectives: In this study, we aimed to provide real life data by reporting our experience with omalizumab in the treatment of chronic spontaneous urticaria. Methods: A retrospective...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2022-10-01
|
| Series: | Dermatology Practical & Conceptual |
| Subjects: | |
| Online Access: | https://www.dpcj.org/index.php/dpc/article/view/2053 |